
Alliance will provide a new therapy for rare CNS disease
Minoryx and Neuraxpharm have agreed a strategic alliance to provide a new therapy for rare CNS disease patients in Europe. The companies have entered into a license agreement for the European rights to leriglitazone, currently under European Medicines Agency (EMA) review for the orphan indication X-linked Adrenoleukodystrophy… Read More
